GPCR Stock Jumps As Obesity-Drug Race Gets A New Twist
Structure Therapeutics Inc. shares rose 5.3% to $38.79 in late New York trading on Thursday, outpacing the broader biotech tape as investors kept the drug developer in the obesity-pill trade. The stock touched $38.85, with volume of about 499,000 shares. The move came with no new company release in the past two days. That matters because the next real test for Structure is not a same-day headline, but whether aleniglipron, its experimental oral GLP-1 drug, can move cleanly into Phase 3 and hold up against larger rivals.